Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study - Papp, K A; Kaufmann, R; Thaçi, D (J Eur Acad Dermatol Venereol, 2013)
et al.